Qiagen N.V. (QGEN)
NYSE: QGENHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Oct 7, 4:00 PM ET · Delayed 15 min
QGEN stock chart
Technical analysisKey statistics
All statistics- Market cap
- $9.25B
- P/E (TTM)
- 22.74
- Forward P/E
- 17.14
- EPS (TTM)
- $1.97
- Dividend yield
- 0.81% ($0.363)
- Ex-dividend date
- Jul 7, 2026
- 52-week range
- 32.53 – 57.82
- Day range
- 44.78 – 46.09
- Volume / Avg
- 2.58M / 2.75M
- Beta
- —
- Shares outstanding
- 206.50M
- Next earnings
- Nov 3, 2026
52-week range
QGEN stock today
Qiagen N.V. (QGEN) closed at $44.79 on Oct 7, down 1.88% (-$0.86), versus the S&P 500's 0.22% decline. Shares are 22.5% below their 52-week high of $57.82, set on Jan 20, 2026 and 37.7% above the 52-week low of $32.53, in the middle of the past year's range. QGEN is down 0.4% year to date, underperforming the S&P 500 (+14.0%). Over the past 12 months, the stock has lost 4.3%.
At 22.7x trailing earnings, Qiagen N.V. trades below the peer-group median of 62.5x. Its forward P/E of 17.1x is lower than the trailing multiple, which means analysts expect earnings to rise over the next year. Qiagen N.V.'s next earnings report is expected on Nov 3, 2026. Qiagen N.V. pays an annual dividend of $0.363 per share, a 0.81% yield at the current price.
Summary generated from market data by MetaCap's automated system. Methodology
About Qiagen N.V.
Company profileQiagen N.V. provides sample to insight solutions that transform biological samples into molecular insights worldwide. The company offers sample technology consumables, such as nucleic acid stabilization and purification kits for sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids; and instruments for nucleic acid purification, quality control, and accessories.
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- CEO
- Mr. Jonathan M. Pratt
- Headquarters
- Venlo
- Employees
- 5,500
- IPO year
- 2026
- Website
- qiagen.com
Financial highlights
Full financialsIn fiscal 2025, Qiagen N.V. generated $2.09 billion in revenue, up 5.7% from fiscal 2024, its 2nd consecutive year of revenue growth. Net income was $424.9 million (+408.3% year over year), for a net margin of 20.3% versus a median of 19.2% in the prior 5 years. Gross margin was 62.2% (up from 48.9%) and operating margin 22.3%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $2.09B | $1.98B | $1.97B | $2.14B | $2.25B |
| Growth | +5.65% | +0.66% | -8.23% | -4.89% | +20.39% |
| Net income | $424.88M | $83.59M | $341.30M | $423.21M | $512.60M |
| EPS (diluted) | $1.94 | $0.37 | $1.48 | $1.84 | $2.21 |
Analyst forecast
ForecastConsensus (16 analysts)
buy
Avg. price target
$47.27+5.54%
- Strong buy 5
- Buy 4
- Hold 7
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Next report
- Nov 3, 2026
- EPS estimate
- $0.62
Dividends
Dividend history- Annual dividend
- $0.363
- Dividend yield
- 0.81%
- Last payment
- $0.35
- Ex-dividend date
- Jul 7, 2026
QGEN news
All QGEN newsQiagen N.V. peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| KRYSKrystal Biotech Inc. | 324.57 | -0.69% | $9.61B | vs QGEN |
| KYMRKymera Therapeutics Inc. | 108.35 | +2.24% | $8.91B | vs QGEN |
| PCVXVaxcyte Inc. | 66.96 | +0.39% | $9.96B | vs QGEN |
| TWSTTwist Bioscience Corporation | 155.65 | -6.78% | $10.32B | vs QGEN |
| IBRXImmunityBio Inc. | 9.75 | +0.62% | $10.33B | vs QGEN |
| RGENRepligen Corporation | 167.22 | -4.37% | $10.62B | vs QGEN |
| TECHBio-Techne Corp | 72.53 | +0.14% | $11.37B | vs QGEN |
| IMVTImmunovant Inc. | 32.04 | -0.22% | $6.62B | vs QGEN |
Indexes, lists and sector
Appears in lists
Qiagen N.V. stock FAQ
What is Qiagen N.V.'s stock price today?
QGEN last traded at $44.79 as of Oct 7, 4:00 PM EDT, down 1.88% on the day. Prices are delayed at least 15 minutes.
Does Qiagen N.V. pay a dividend?
Yes. Qiagen N.V. pays $0.363 per share annually, a 0.81% yield. The most recent dividend of $0.35 had an ex-dividend date of Jul 7, 2026.
When is Qiagen N.V.'s next earnings date?
Qiagen N.V. is expected to report earnings on Tuesday, November 3, 2026. Analysts expect EPS of $0.62.
What is QGEN's P/E ratio?
QGEN trades at a trailing P/E ratio of 22.74 and a forward P/E of 17.14, compared with a median of 62.5 for its closest peers.
Who is Qiagen N.V.'s CEO?
Mr. Jonathan M. Pratt is the chief executive officer of Qiagen N.V., which has about 5,500 employees.
Has QGEN ever split its stock?
Yes. The most recent QGEN stock split was a 962-for-1000 split on Jan 25, 2017, one of 3 splits on record.
What is the QGEN 52-week high?
The 52-week high for QGEN is $57.82 and the 52-week low is $32.53. The stock is currently 22.5% below its high.